ÄãºÃ£¬»¶Ó­À´µ½¾­¹ÜÖ®¼Ò [µÇ¼] [×¢²á]

ÉèΪÊ×Ò³ | ¾­¹ÜÖ®¼ÒÊ×Ò³ | Êղر¾Õ¾

¼××´ÏÙ΢СÈéÍ·×´°©µÄÐÎ̬ѧºÍÃâÒß×éÖ¯»¯Ñ§Ñо¿_ҽѧ±ÏÒµÂÛÎÄ

·¢²¼Ê±¼ä£º2015-03-26 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳
¼××´ÏÙ΢СÈéÍ·×´°©µÄÐÎ̬ѧºÍÃâÒß×éÖ¯»¯Ñ§Ñо¿_ҽѧ±ÏÒµÂÛÎÄ ¡¾ÕªÒª¡¿ Ä¿µÄ£º¹Û²ì¼××´ÏÙ΢СÈéÍ·×´°©µÄÁÙ´²²¡Àí²¢¼ì²âÆäÃâÒß±íÐÍ£¬Ì½ÌÖÏà¹Ø¼²²¡µÄ¼ø±ðÕï¶Ï¡£·½·¨£º¹âѧÏÔ΢¾µÏ¹۲ì223Àý¼××´ÏÙ΢СÈéÍ·×´°©µÄ×éÖ¯ÐÎ̬£»¶Ô74Àý¼××´ÏÙ΢СÈéÍ·×´°©¡¢32Àý¼××´ÏÙÔöÉúÐÔ²¡±äÐÐÃâÒß×éÖ¯»¯Ñ§·½·¨±ê¼Çϸ°û½Çµ°°×19£¨CK19£©¡¢¼äƤϸ°û£¨MC£©¡¢Ï¸°û𤸽Äý¼¯ËØ3£¨Galectin-3£©¡¢CD56£¬¸´Ï°Ïà¹ØÎÄÏס£½á¹û£ºÔÚ223Àý¼××´ÏÙ΢СÈéÍ·×´°©ÖÐÒÔÂËÅÝ×´ÅÅÁÐΪÖ÷ÕßÕ¼38.6%£¨86/223£©£¬ºËµÄÌØÕ÷²»µäÐÍÕßÕ¼13.9%£¨31/223£©¡£ÔÚ74Àý¼××´ÏÙ΢СÈéÍ·×´°©ÖÐCK19¡¢MC¡¢Galectin-3¡¢CD56ÑôÐÔ±í´ïÂÊ·Ö±ðΪ100.0£¥¡¢98.6%¡¢98.6%¡¢4.1%£»ÔÚ32ÀýÔöÉúÐÔ²¡±äÖÐ4ÕßÑôÐÔ±í´ïÂÊ·Ö±ðΪ37.5£¥¡¢12.5%¡¢18.8%¡¢68.8%¡£½áÂÛ£º²¿·Ö¼××´ÏÙ΢СÈéÍ·×´°©Ï¸°ûÒÔÂËÅÝ×´ÅÅÁÐΪÖ÷£¬ºËµÄÌØÕ÷²»¹»µäÐÍ£¬Õï¶Ï½ÏΪÀ§ÄÑ¡£¸ù¾ÝÂËÅÝϸ°ûÔöÉú»îÔ¾£¬Ï¸°ûºË¾ßÓÐÈéÍ·×´°©µÄ»ù±¾Ìص㣬²¡±äÓëÖÜΧÂËÅݽØÈ»²»Í¬£¬ÇÒÖ×ÁöÐÔÂËÅÝ´©²åÓÚÓ²»¯¼äÖÊ»òÕý³£ÂËÅÝÖ®¼ä£¬¿ÉÓëÔöÉúÐÔ²¡±ä¼ø±ð¡£CK19¡¢Galectin-3¡¢MCÃÖÂþÐÔÖÐÇ¿ÑôÐÔ±í´ï£¬CD56ÒõÐÔ±í´ï¶ÔÆäÕï¶ÏÓÐÖØÒª¼ÛÖµ£¬ÁªºÏÓ¦ÓÿÉÒÔÌá¸ßÕï¶ÏµÄ׼ȷÐÔºÍÌØÒìÐÔ¡£ ¡¾¹Ø¼ü´Ê¡¿ ¼××´ÏÙÖ×Áö¡¤°©£¬ÈéÍ·×´¡¤Î¢Ð¡°©¡¤Ï¸°û½Çµ°°×19¡¤°ëÈéÄýËØ-3¡¤ÉÏƤ¡¤·Ö»¯¿¹Ô­´Ø56¡¤ÃâÒß×éÖ¯»¯Ñ§ Immunohistochemical and morphological characteristics of the papillary thyroid microcarcinoma ¡¡REN Yu-bo, ZHOU Geng-yin, ZHANG Xue-dong, LI Yu-hong, JIA Ai-hua, DONG Xin-qian¡¡1Department of Pathology, People¡¯s Hospital of Liaocheng £¨Liaocheng 252000, China£©2Department of Pathology, Qilu Hospital of Shandong University £¨Jinan 250012, China£© ¡¾ABSTRACT¡¿ Objctive: To investigate the immunohistochemical and morphological characteristics of the papillary thyroid microcarcinoma(PTM), and differential diagnosis of the related disease. Methods: The morphological characteristics of 223 patients with PTM were observed under light microscope. Seventy-four cases of PTM and 32 cases of proliferative lesion of thyroid were observed under light microscope with stains of hematoxylin and eosin and immunohistochemical staining. The antibody included CK19, MC, Galectin-3 and CD56. Results: Eighty-six cases were follicular-patterned and 31 cases nuclear features were untypical in 223 cases of PTM. The positive expression rates of CK19¡¢MC¡¢Galectin-3¡¢CD56 were 100.0%, 98.6%, 98.6% and 4.1% in 74 cases of PTM, and were 37.5£¥, 12.5%, 18.8%, 68.8% in proliferative lesion of thyroid, respectively. Conclusion: Some cases of PTM show a follicular-patterned and the nuclear features. It is untypical compared with classical papillary thyroid carcinoma. It can be differentiated from proliferative lesion with absence of envelope, obviously various and unusually proliferated follicular cells, sclerotic stroma, neoplastic follicles among the collagen and normal follicles. The wide and intensive expression of CK19, Galectin-3, and the negative expression of CD56 are extremely useful in the diagnosis of PTM, four-marker panel with CK19, Galectin-3, MC and CD56 can improve the specificity and accuracy of the differential diagnosis of PTM. ¡¾KEY WORDS¡¿ Thyroid neoplams¡¤Carcinoma, papillary¡¤Microcarcinoma¡¤Cytokeratin 19¡¤Epithelium¡¤Cluster differentiation 56 ¼××´ÏÙ΢С°©ÊÇÖ¸Ö±¾¶1 cmÒÔϵļ××´ÏÙ°©£¬ÆäÖоø´ó¶àÊýÊǼ××´ÏÙÈéÍ·×´°©£¨papillary thyroidcarcinoma£¬PTC£©£¬³ÆΪ¼××´ÏÙ΢СÈéÍ·×´°©£¨papillary thyroid microcarcinoma£¬PTM£©¡£Ëæ׎¡¿µÌå¼ì¹¤×÷¶Ô¼××´ÏÙ¼²²¡µÄÖØÊӺͳ¬ÉùÒýµ¼Ï¼××´ÏÙ½á½ÚϸÕë³éÎüϸ°ûѧ¼¼ÊõµÄÈÕÕé³ÉÊìºÍ¹ã·º¿ªÕ¹£¬PTMµÄ¼ì³öÂÊÖð½¥Éý¸ß£¬ÊÖÊõÇгýµÄÖ×ÁöÔ½À´Ô½Î¢Ð¡£¬²¡ÀíÕï¶ÏÔ½À´Ô½À§ÄÑ¡£¹Û²ìPTMµÄ²¡Àí×é֯ѧÌص㣬ѰÕÒÌØÒìÐÔ±êÖ¾Î½¨Á¢¿É¿¿¡¢¿ÉÐеļì²âÊֶΣ¬¶ÔÓÚ¼××´ÏÙÖ×ÁöµÄÔçÆÚÕï¶Ï¾ßÓÐÖØÒªÁÙ´²¼ÛÖµ¡£½üÄêÀ´¹ØÓÚPTCµÄÃâÒß×éÖ¯»¯Ñ§£¨immunohistochemical£¬IHC£©Ñо¿ÒÑÓн϶౨µÀ£¬Ö÷ÒªÊÇϸ°û½Çµ°°×19£¨cytokeratin 19£¬CK19£©¡¢Ï¸°û𤸽Äý¼¯ËØ3£¨Galectin-3£©¡¢E-¸ÆÕ³Á¬ËØ£¨E-cadherin£©¡¢HBME-1µÈ¿¹Ìå£Û1£Ý£¬¹ØÓÚ¼äƤϸ°û£¨mesothelial cell£¬MC£©¡¢CD56µÄ±¨µÀ½ÏÉÙ¡£±¾Ñо¿¸´Ï°Ïà¹ØÎÄÏ×£¬Ì½ÌÖPTMµÄ²¡Àí×é֯ѧºÍÃâÒß±íÐÍÌص㼰Æä¼ø±ðÕï¶Ï¡£ 1¡¡²ÄÁÏÓë·½·¨ 1.1¡¡²ÄÁÏ ÊÕ¼¯ÁijÇÊÐÈËÃñÒ½Ôº²¡Àí¿Æ2006Äê1ÔÂ2008Äê12ÔÂÐм××´ÏÙÊÖÊõ»¼ÕߵIJ¡Àí±ê±¾1 491Àý¡£3Ãû²¡Àíҽʦ¸´²éËùÓв¡Àý¡£ÆäÖÐPTC 441Àý£¬ ·ûºÏPTMÕß223Àý£¬ÆäÖÐÄÐ28Àý£¬Å®195Àý£¬ÄÐŮ֮±ÈΪ1¡Ã6.96¡£ÄêÁäΪ20¡«78Ë꣬ƽ¾ùÄêÁä45.7Ëꡣѡȡ32Àý¼××´ÏÙÔöÉúÐÔ²¡±ä£¨°üÀ¨ÏÙÁöÑùÔöÉú26Àý¡¢ÈéÍ·×´ÔöÉú6Àý£©×÷Ϊ¶ÔÕÕ×飬74ÀýPTM×÷ΪÑо¿×飬½øÐÐIHC¼ì²â¡£ 1.2·½·¨ ËùÓв¡Àý¾ù¾­4%¼×È©¹Ì¶¨£¬×éÖ¯¿éÓÉÈ«×Ô¶¯ÍÑË®»ú´¦Àí¡£IHCԤʵÑéÑ¡È¡¾­µäÐÍPTC¡¢ÂËÅÝÐÍPTC¡¢ÔöÉúÐÔ½á½Ú¸÷4ÀýÖƱ¸×é֯оƬ£¬·Ö±ðÐÐ48ÖÖ¿¹ÌåIHC¼ì²é£¬°üÀ¨³£Óÿ¹ÌåºÍ¿ÆÊÒ³£±¸¿¹Ìå¡£Õë¶ÔԤʵÑé½á¹ûÑ¡È¡CK19¡¢MC¡¢Galectin-3¡¢CD56×÷ΪʵÑ鿹Ìå¡£²ÉÓü´ÓÃÐÍ·ÇÉúÎïËØElivisionTM Plus¼ì²âÊÔ¼ÁºÐ£¬ËùÓõ¥¿Ë¡¿¹Ìå¾ù¹ºÓÚ¸£ÖÝÂõÐÂÉúÎï¼¼Êõ¿ª·¢ÓÐÏÞ¹«Ë¾£¬°´²úƷ˵Ã÷Êé²½Öè½øÐÐȾɫ²Ù×÷¡£PBSÌæ´úÒ»¿¹×÷ΪÒõÐÔ¶ÔÕÕ¡£ 1.3 PTCµÄ×é֯ѧ¹Û²ìÖ¸±ê Ö×Áö´óС¡¢Éú³¤·½Ê½¡¢×éÖ¯½á¹¹¡¢ºËµÄÌØÕ÷¡¢Ï¸°ûÖʱíÏֵȡ£ 1.4 PTCµÄÕï¶Ï±ê×¼
¾­¹ÜÖ®¼Ò¡°Ñ§µÀ»á¡±Ð¡³ÌÐò
  • ɨÂë¼ÓÈë¡°¿¼ÑÐѧϰ±Ê¼ÇȺ¡±
ÍƼöÔĶÁ
¾­¼ÃѧÏà¹ØÎÄÕÂ
±êÇ©ÔÆ
¾­¹ÜÖ®¼Ò¾«²ÊÎÄÕÂÍƼö